ARCA biopharma Inc. (ABIO) Financial Statements (2025 and earlier)

Company Profile

Business Address 855 OAK GROVE AVE.
MENLO PARK, CA 94025
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments37,431,00042,445,00053,359,00049,071,0008,363,0006,608,000
Cash and cash equivalents37,431,00042,445,00053,359,00049,071,0008,363,0006,608,000
Other current assets 161,000254,0001,062,000897,000117,000169,000
Other undisclosed current assets      
Total current assets:37,592,00042,699,00054,421,00049,968,0008,480,0006,777,000
Noncurrent Assets
Operating lease, right-of-use asset247,000343,000437,000428,00022,000
Property, plant and equipment10,00025,00048,00021,00010,00024,000
Other noncurrent assets12,00018,00018,00012,00024,00024,000
Total noncurrent assets:269,000386,000503,000461,00056,00048,000
TOTAL ASSETS:37,861,00043,085,00054,924,00050,429,0008,536,0006,825,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities637,0001,132,0003,498,0003,499,000926,000793,000
Employee-related liabilities925,000815,000129,000150,000
Accounts payable362,000334,0001,117,0001,773,000418,000230,000
Accrued liabilities275,000798,0001,456,000911,000379,000413,000
Other undisclosed current liabilities      
Total current liabilities:637,0001,132,0003,498,0003,499,000926,000793,000
Noncurrent Liabilities
Long-term debt and lease obligation:   383,000409,000  
Liabilities, other than long-term debt204,000280,000    
Operating lease, liability204,000280,000383,000409,000 
Other undisclosed noncurrent liabilities   (383,000)(409,000)  
Total noncurrent liabilities:204,000280,000383,000409,000  
Total liabilities:841,0001,412,0003,881,0003,908,000926,000793,000
Equity
Equity, attributable to parent37,020,00041,673,00051,043,00046,521,0007,610,0006,032,000
Common stock14,00014,00014,00010,0002,00014,000
Additional paid in capital225,747,000225,061,000224,505,000200,665,000152,024,000144,952,000
Accumulated deficit(188,741,000)(183,402,000)(173,476,000)(154,154,000)(144,416,000)(138,934,000)
Other undisclosed equity, attributable to parent      
Other undisclosed equity      
Total equity:37,020,00041,673,00051,043,00046,521,0007,610,0006,032,000
TOTAL LIABILITIES AND EQUITY:37,861,00043,085,00054,924,00050,429,0008,536,0006,825,000

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(7,296,000)(10,596,000)(19,335,000)(9,766,000)(5,814,000)(8,118,000)
Operating loss:(7,296,000)(10,596,000)(19,335,000)(9,766,000)(5,814,000)(8,118,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 (5,000)    
Interest and debt expense   (9,000)(7,000)(8,000)
Loss from continuing operations before equity method investments, income taxes:(7,296,000)(10,601,000)(19,335,000)(9,775,000)(5,821,000)(8,126,000)
Other undisclosed income from continuing operations before income taxes   13,00028,000172,000162,000
Loss from continuing operations before income taxes:(7,296,000)(10,601,000)(19,322,000)(9,747,000)(5,649,000)(7,964,000)
Income tax benefit    9,000167,00031,000
Loss from continuing operations:(7,296,000)(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)
Loss before gain (loss) on sale of properties:(19,322,000)(9,738,000)(5,482,000)(7,933,000)
Net loss:(7,296,000)(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)
Other undisclosed net income attributable to parent1,957,000675,000    
Net loss available to common stockholders, diluted:(5,339,000)(9,926,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(7,296,000)(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)
Comprehensive loss:(7,296,000)(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)
Other undisclosed comprehensive income, net of tax, attributable to parent      2,000
Comprehensive loss, net of tax, attributable to parent:(7,296,000)(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,931,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: